Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05029856
Registration number
NCT05029856
Ethics application status
Date submitted
25/08/2021
Date registered
1/09/2021
Date last updated
31/05/2022
Titles & IDs
Public title
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
Query!
Scientific title
A Randomized, Observer-Blinded, Phase 1/2 Study With an Open-Label Group to Evaluate the Safety and Immunogenicity of SII Vaccine Constructs Based on SARS-CoV-2 Variants in Adults
Query!
Secondary ID [1]
0
0
2019nCoV-102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Covid19
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - SII B.1.351
Other interventions - SII B.1.351
Other interventions - SII Bivalent
Other interventions - SII Bivalent
Other interventions - SII B.1.617.2
Experimental: Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant - 2 doses of 3 µg SII B.1.351 Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
Experimental: Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant - 2 doses of 5 µg SII B.1.351 Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
Experimental: Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant - 1 dose of 3 µg SII B.1.351 Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
Experimental: Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant - 1 dose of 5 µg SII B.1.351 Vaccine + 50 µg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
Experimental: Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant - 2 doses of 6 µg SII Bivalent Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
Experimental: Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant - 2 doses of 10 µg SII Bivalent Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
Experimental: Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant - 2 doses of 5 µg SII B.1.617.2 Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
Experimental: Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant - 1 doses of 5 µg SII B.1.617.2 Vaccine+ 50 µg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.
Other interventions: SII B.1.351
Intramuscular (deltoid) injections of 3 µg SII B.1.351 and 50 µg Matrix-M1 Adjuvant,
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Other interventions: SII B.1.351
Intramuscular (deltoid) injections of 5 µg SII B.1.351 and 50 µg Matrix-M1 Adjuvant,
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Other interventions: SII Bivalent
Intramuscular (deltoid) injections of 6 µg SII Bivalent and 50 µg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
Other interventions: SII Bivalent
Intramuscular (deltoid) injections of 10 µg SII Bivalent and 50 µg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
Other interventions: SII B.1.617.2
Intramuscular (deltoid) injections of 5 µg SII B.1.617.2 and 50 µg Matrix-M1 Adjuvant,
1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMT
Query!
Assessment method [1]
0
0
(MN50) geometric mean titers (GMTs) to the SARS-CoV-2 B.1.351 (Beta) variant at Day 14 (one-dose regimen; Groups C and D) and Day 35 (two-dose regimen; Groups A and B);
Query!
Timepoint [1]
0
0
Day 14 and Day 35
Query!
Primary outcome [2]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs
Query!
Assessment method [2]
0
0
Seroconversion rates (SCRs) or seroresponse rates (SRRs) (proportion of participants who achieve = 4-fold increase from baseline) in MN50 titer concentrations to the SARS-CoV-2 B.1.351 (Beta) variant following their last vaccination.
Query!
Timepoint [2]
0
0
Day 14 and Day 35
Query!
Primary outcome [3]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as GMT
Query!
Assessment method [3]
0
0
Neutralizing antibody MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant at Day 14 (one-dose regimen; Group H) and Day 35 (two-dose regimen; Group G);
Query!
Timepoint [3]
0
0
Day 14 and Day 35
Query!
Primary outcome [4]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/SRRs
Query!
Assessment method [4]
0
0
SCRs/SRRs (proportion of participants who achieve = 4-fold increase from baseline) in MN50 titer concentrations to the SARS-CoV-2 Delta variant following their last vaccination.
Query!
Timepoint [4]
0
0
Day 14 and Day 35
Query!
Primary outcome [5]
0
0
Incidence, duration, and severity of solicited local and systemic adverse events (AEs)
Query!
Assessment method [5]
0
0
Incidence, duration, and severity of solicited local and systemic adverse events (AEs) for 7 days following each vaccination
Query!
Timepoint [5]
0
0
Day 0 to Day 7
Query!
Primary outcome [6]
0
0
Incidence, duration, severity, and relationship of unsolicited AEs through 28 days
Query!
Assessment method [6]
0
0
Incidence, duration, severity, and relationship of unsolicited AEs through 28 days after the last vaccination
Query!
Timepoint [6]
0
0
Day 0 to Day 28
Query!
Primary outcome [7]
0
0
Incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs)
Query!
Assessment method [7]
0
0
Incidence and relationship of medically attended adverse events (MAAEs), adverse events of special interest (AESIs) (predefined list), and serious adverse events (SAEs) throughout the study.
Query!
Timepoint [7]
0
0
Day 0 to Day 217
Query!
Secondary outcome [1]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated patients
Query!
Assessment method [1]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [1]
0
0
Day 0 to Day 189
Query!
Secondary outcome [2]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline
Query!
Assessment method [2]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [2]
0
0
Day 0 to Day 217
Query!
Secondary outcome [3]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated patients
Query!
Assessment method [3]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [3]
0
0
Day 0 to Day 189
Query!
Secondary outcome [4]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline.
Query!
Assessment method [4]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [4]
0
0
Day 0 to Day 217
Query!
Secondary outcome [5]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline
Query!
Assessment method [5]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [5]
0
0
Day 0 to Day 217
Query!
Secondary outcome [6]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants
Query!
Assessment method [6]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [6]
0
0
Day 0 to Day 189
Query!
Secondary outcome [7]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in participants seronegative at baseline
Query!
Assessment method [7]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [7]
0
0
Day 0 to Day 217
Query!
Secondary outcome [8]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta)expressed as SCRs/ SRRs in previously vaccinated participants
Query!
Assessment method [8]
0
0
MN50 GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variants and to the ancestral SARS-CoV-2 strain at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [8]
0
0
Day 0 to Day 189
Query!
Secondary outcome [9]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants
Query!
Assessment method [9]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [9]
0
0
Day 0 to Day 189
Query!
Secondary outcome [10]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline
Query!
Assessment method [10]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [10]
0
0
Day 0 to Day 217
Query!
Secondary outcome [11]
0
0
IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in participants seronegative at baseline
Query!
Assessment method [11]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [11]
0
0
Day 0 to Day 217
Query!
Secondary outcome [12]
0
0
IgG geometric mean concentrations (GMCs) to the B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein in previously vaccinated participants
Query!
Assessment method [12]
0
0
IgG geometric mean concentrations (GMCs) to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [12]
0
0
Day 0 to Day 189
Query!
Secondary outcome [13]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in previously vaccinated participants
Query!
Assessment method [13]
0
0
GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [13]
0
0
Day 0 to Day 189
Query!
Secondary outcome [14]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as GMFR in participants seronegative at baseline
Query!
Assessment method [14]
0
0
GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [14]
0
0
Day 0 to Day 217
Query!
Secondary outcome [15]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in previously vaccinated participants
Query!
Assessment method [15]
0
0
GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [15]
0
0
Day 0 to Day 189
Query!
Secondary outcome [16]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.351 (Beta) expressed as SCRs/SRRs in participants seronegative at baseline
Query!
Assessment method [16]
0
0
GMTs to the SARS-CoV-2 B.1.351 (Beta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein at Days 0, 14, and 189 at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [16]
0
0
Day 0 to Day 217
Query!
Secondary outcome [17]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in participants seronegative at baseline
Query!
Assessment method [17]
0
0
GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [17]
0
0
Day 0 to Day 217
Query!
Secondary outcome [18]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as GMFR in previously vaccinated participants
Query!
Assessment method [18]
0
0
GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [18]
0
0
Day 0 to Day 189
Query!
Secondary outcome [19]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in participants seronegative at baseline
Query!
Assessment method [19]
0
0
GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 21, 35, and 217 in participants seronegative at baseline.
Query!
Timepoint [19]
0
0
Day 0 to Day 217
Query!
Secondary outcome [20]
0
0
Human Angiotensin-Converting Enzyme 2 (hACE2) receptor binding inhibition assay GMT to the SARS-CoV-2 B.1.617.2 (Delta) expressed as SCRs/SRRs in previously vaccinated participants
Query!
Assessment method [20]
0
0
GMTs to the SARS-CoV-2 B.1.617.2 (Delta) variant S proteins and to the ancestral SARS-CoV-2 strain S protein and at Days 0, 14, and 189 in previously vaccinated individuals
Query!
Timepoint [20]
0
0
Day 0 to Day 189
Query!
Eligibility
Key inclusion criteria
1. Adults 18 to 64 years of age, inclusive, at screening.
2. Willing and able to give informed consent prior to study enrollment and to comply with
study procedures.
3. Female participants of childbearing potential (defined as any participant who has
experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral
tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at
least 12 consecutive months]) must agree to be heterosexually inactive from at least
28 days prior to enrollment and through the end of the study OR agree to consistently
use a medically acceptable method of contraception listed below from at least 28 days
prior to enrollment and through the end of the study.
1. Condoms (male or female) with spermicide (if acceptable in country)
2. Diaphragm with spermicide
3. Cervical cap with spermicide
4. Intrauterine device
5. Oral or patch contraceptives
6. Norplant®, Depo-Provera®, or other in-country regulatory approved contraceptive
method that is designed to protect against pregnancy
7. Abstinence, as a form of contraception, is acceptable if in line with the
participant's lifestyle
4. Is medically stable, as determined by the investigator (based on a review of health
status, vital signs [to include body temperature], medical history, and targeted
physical examination [to include body weight]). Vital signs must be within medically
acceptable ranges prior to the first vaccination.
5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for
the duration of the study.
For previously vaccinated Participants (Groups C, D and H):
6. Documented receipt of 2 doses of the investigational Novavax vaccine with Matrix-M1
adjuvant (NVX-CoV2373) administered approximately 21 days apart or 2 doses of a
TGA-authorized/approved COVID-19 vaccine administered at least 60 days prior to first
study vaccination.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
64
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
If an individual meets any of the following criteria, he or she is ineligible for this
study:
1. History of laboratory-confirmed (by PCR or serology to SARS-CoV-2) COVID-19 infection
at any time prior to randomization/enrollment.
2. Previous receipt of any investigational or authorized/approved vaccine, prophylactic
or therapeutic agent for the prevention or treatment of SARS-CoV-2 infection, except
for previously vaccinated participants.
3. Participation in research involving receipt of investigational products
(drug/biologic/device) within 90 days prior to first study vaccination.
4. Received influenza vaccination within 14 days prior to first study vaccination, or any
other vaccine within 30 days prior to the first study vaccination.
5. Any known allergies to products contained in the investigational product.
6. Any history of anaphylaxis to any prior vaccine.
7. Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring
ongoing immunomodulatory therapy.
8. Chronic administration (defined as > 14 continuous days) of immunosuppressants,
systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to
first study vaccination.
9. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90
days prior to first study vaccination.
10. Active cancer (malignancy) on therapy within 3 years prior to first study vaccination
(with the exception of adequately treated non-melanomatous skin carcinoma or lentigo
maligna and uterine cervical carcinoma in situ without evidence of disease, at the
discretion of the investigator).
11. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to
the end of study.
12. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to
the first study vaccine dose that, in the opinion of the investigator, might interfere
with protocol compliance.
13. Any other condition that, in the opinion of the investigator, would pose a health risk
to the participant if enrolled or could interfere with evaluation of the study vaccine
or interpretation of study results (including neurologic or psychiatric conditions
likely to impair the quality of safety reporting).
14. Study team member or immediate family member of any study team member (inclusive of
Sponsor, CRO, and study site personnel involved in the conduct or planning of the
study).
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
4/02/2022
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2022
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
0
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Australian Clinical Research Network (ACRN) - Maroubra
Query!
Recruitment hospital [2]
0
0
Holdsworth House Medical Practice - Sydney - Sydney
Query!
Recruitment hospital [3]
0
0
University Hospital Geelong-Barwon Health - Geelong
Query!
Recruitment hospital [4]
0
0
Emeritus Research - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [2]
0
0
2010 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
3320 - Geelong
Query!
Recruitment postcode(s) [4]
0
0
3124 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novavax
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, observer-blinded, Phase 1/2 study with an open-label group to evaluate
the safety and immunogenicity of 3 novel SARS-CoV-2 variant vaccine constructs adjuvanted
with Matrix-M1 adjuvant. Investigational products will include a monovalent SII SARS-CoV-2
B.1.351 (Beta) variant vaccine (SII B.1.351), a bivalent SII vaccine containing antigen for
both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent), and a
monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine (SII B.1.617.2).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05029856
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Development
Query!
Address
0
0
Novavax
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05029856
Download to PDF